JAZZ Jazz Pharmaceuticals plc

0  0%
Previous Close 153.11
Open 152.56
Price To book 4.88
Market Cap 9.13B
Shares 59,742,000
Volume 220,160
Short Ratio 1.84
Av. Daily Volume 623,616

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received October 11, 2010.
Phase 2 enrollment initiation announced February 8, 2017.
Excessive Sleepiness in Parkinson's Disease
Phase 2/3 positive data released April 24, 2017. sNDA filing due 4Q 2017.
Pediatric narcolepsy patients with cataplexy
Phase 3 data due 2Q 2017.
Excessive sleepiness associated with narcolepsy
Phase 3 data released March 20, 2017 - primary endpoints met.
Excessive sleepiness associated with obstructive sleep apnea
Phase 3 trial initiated 3Q 2016.
VOD in high-risk patients following hematopoietic stem cell transplantation
Announced April 3, 2017 that rolling NDA submission has been completed. Priority review has been requested.
Acute myeloid leukemia

Latest News

  1. Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017
  2. Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy
  3. Jazz Pharmaceuticals, Inc. -- Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from negative
  4. Time for some game theory: A look at Jazz Pharma’s latest settlement
  5. Should You Drop What You're Doing and Buy Jazz Pharmaceuticals Stock?
  6. This Rival Might Swipe 20% Of Jazz's Sleep Business, But Stock Perks Up
  7. Market Cheers Jazz Pharmaceuticals Patent Settlement
  8. Jazz Pharma Settles 2010 Xyrem Patent Lawsuit
  9. Trevena, Synergy Lead Biotech Movers
  10. Jazz Pharmaceuticals stock surges 7% on settlement with Hikma over generic drug
  11. Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation
  12. Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA
  13. Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia
  14. Blog Coverage Jazz Pharmaceuticals Inks License Agreement with Nippon Shinyaku
  15. Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue?
  16. Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan
  17. Why You're Smart to Buy Jazz Pharmaceuticals plc
  18. Blog Coverage Stemline Announces Completion of Enrollment for the Stage 3 SL-401 Pivotal Trial
  19. Jazz Sleep Disorder Drug Positive in Phase III Studies
  20. Jazz Pharma Isn't Dozing; Stock Breaks Out On Sleep Apnea Trial